Primaquine
Primaquine is a small molecule pharmaceutical. Primaquine was first approved as Aralen phosphate w/ primaquine phosphate on 1982-01-01. It is used to treat falciparum malaria, malaria, and vivax malaria in the USA.
Download report
Favorite
COVID-19
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| primaquine phosphate | ANDA | 2022-08-19 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| falciparum malaria | EFO_0007444 | D016778 | B50 |
| malaria | EFO_0001068 | D008288 | B54 |
| vivax malaria | EFO_0007445 | D016780 | B51 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
91 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malaria | D008288 | EFO_0001068 | B54 | 6 | 8 | 9 | 11 | 7 | 36 |
| Vivax malaria | D016780 | EFO_0007445 | B51 | 2 | 8 | 10 | 9 | 8 | 34 |
| Falciparum malaria | D016778 | EFO_0007444 | B50 | 1 | 7 | 5 | 8 | 5 | 23 |
| Glucosephosphate dehydrogenase deficiency | D005955 | EFO_0007287 | 2 | 1 | — | 2 | 2 | 7 | |
| Parasitic diseases | D010272 | EFO_0001067 | B88 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | 1 | 1 | — | 1 | 2 | ||
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | 1 | — | 1 | 2 |
| Pneumocystis pneumonia | D011020 | EFO_0007448 | B59 | — | — | 1 | — | 1 | 2 |
| Asymptomatic diseases | D058070 | — | 1 | 2 | — | — | 2 | ||
| Covid-19 | D000086382 | U07.1 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 4 | 1 | — | — | — | 4 | ||
| Pharmacokinetics | D010599 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PRIMAQUINE |
| INN | primaquine |
| Description | Primaquine is an N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia. It has a role as an antimalarial. It is an aminoquinoline, a N-substituted diamine and an aromatic ether. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc(NC(C)CCCN)c2ncccc2c1 |
Identifiers
| PDB | — |
| CAS-ID | 90-34-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL506 |
| ChEBI ID | 8405 |
| PubChem CID | 4908 |
| DrugBank | DB01087 |
| UNII ID | MVR3634GX1 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,897 documents
View more details
Safety
Black-box Warning
Black-box warning for: Primaquine phosphate
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
41 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more